BCIQ Profiles

Company Profile Report

Lynparza shows PFS benefit of 3.6 months in pancreatic cancer

AstraZeneca’s Lynparza olaparib has hit the minimum three-month benefit that oncologists were hoping to see in pancreatic cancer. Data presented Sunday at ASCO position the PARP inhibitor to become the first targeted agent to

Read the full 347 word article

How to gain access

Continue reading with a
two-week free trial.